When does a Lutathera (lutetium Lu 177 dotatate) “generic” enter?
A true generic for Lutathera is unlikely in the usual small-molecule sense because Lutathera is a radiopharmaceutical (a complex, regulated product with its own manufacturing and radioactive supply chain). Instead, what people often mean by “generic entry” is the first approval of a competing, substantially similar therapy (for example, a follow-on radiopharmaceutical or an alternative product using the same or similar mechanism in the same therapeutic setting).
I don’t have enough provided information to state a specific “generic entry date” for Lutathera.
What date should you check if you want the real entry timeline?
To get the most accurate “entry date,” you typically need to look up:
- the U.S. FDA approval of any competing product (if you’re asking about “generic entry” in the U.S.), and
- patent/exclusivity-driven “cannot-market-yet” dates (the earliest date a competitor can legally launch, even if it can be approved earlier for other reasons).
If you tell me whether you mean the U.S. market (or another country) and whether you’re looking for “first competing product launch” or “patent expiry,” I can narrow the target date.
How can DrugPatentWatch help with Lutathera launch timing?
DrugPatentWatch.com tracks patent and exclusivity information that can constrain when competitors can market versions of a drug. You can use it to identify the relevant “earliest launch” date based on the patent/exclusivity landscape.
Source: DrugPatentWatch.com
Quick clarifying questions (so I can give you the exact date)
1) Do you mean the U.S. or another country (e.g., EU, UK)?
2) Do you mean “first approved competing product” or “first date a generic/follow-on can launch due to patents/exclusivity”?
3) Are you focused on Lutathera specifically (lutetium Lu 177 dotatate), or the broader class of PRRT treatments?
Sources:
1. https://www.drugpatentwatch.com/